In a phase 1 trial of 45 adults with HIV-1 on ART, the PD-1-enhanced DNA vaccine ICVAX (1, 2 or 4 mg) caused only mild, transient treatment-related events (83.3% vs 100% placebo); ≥2-fold T-cell responses occurred in 58.3–75% vs 33.3% placebo.
RCTn = 45
Peng et al. Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy